Virax Biolabs CFO Resigns
Ticker: VRAX · Form: 6-K · Filed: Jun 13, 2025 · CIK: 1885827
| Field | Detail |
|---|---|
| Company | Virax Biolabs Group Ltd (VRAX) |
| Form Type | 6-K |
| Filed Date | Jun 13, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, cfo-resignation
TL;DR
Virax Biolabs CFO Jason Davis out as of June 13, 2025. No replacement named.
AI Summary
Virax Biolabs Group Ltd announced on June 13, 2025, the resignation of Jason Davis as Chief Financial Officer and Secretary. The company has not yet appointed a successor.
Why It Matters
The departure of a key financial executive can signal potential financial instability or strategic shifts within a company, impacting investor confidence.
Risk Assessment
Risk Level: medium — The resignation of a CFO without an immediate successor can create uncertainty regarding financial oversight and future strategy.
Key Players & Entities
- Virax Biolabs Group Ltd (company) — Filing company
- Jason Davis (person) — Resigning Chief Financial Officer and Secretary
- June 13, 2025 (date) — Date of resignation announcement
FAQ
Who has resigned from Virax Biolabs Group Ltd?
Jason Davis has resigned as Chief Financial Officer and Secretary.
What is the effective date of Jason Davis's resignation?
The resignation was effective on June 13, 2025.
Has Virax Biolabs Group Ltd appointed a new CFO?
The filing does not indicate that a successor has been appointed.
What is the company's principal executive office address?
The principal executive offices are located at BioCity Glasgow, Bo'Ness Road, Newhouse, Lanarkshire, ML1 SUH, United Kingdom.
What form is this filing?
This is a Form 6-K report.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on June 13, 2025 by Jason Davis regarding Virax Biolabs Group Ltd (VRAX).